Track topics on Twitter Track topics that are important to you
Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...
Get guidance on the practical use of rivaroxaban for the treatment of patients with VTE. British Journal of Cardiology
Japan's Ministry of Health, Labor and Welfare has approved rivaroxaban, or Xarelto, for the secondary prevention and treatmen -More-
Event rates were low, but no major bleeding complications and no thromboembolic events occurred in the ablation group that had rivaroxaban maintained during the AF procedure. Heartwire from Meds...
More findings show similar safety and efficacy rates between the two treatments, whether or not AF patients also have diabetes, suggesting rivaroxaban may be a feasible alternative. Heartwire fr...
(European Society of Cardiology) Atrial fibrillation (AF) patients treated with rivaroxaban for stroke prevention have low rates of bleeding and stroke, reveals real-world data from the XANTUS study p...
HemosIL, a solution developed by Instrumentation Laboratory to test for rivaroxaban, has obtained CE mark approval from Europ -More-
Janssen Pharmaceuticals and its development partner, Bayer HealthCare, have initiated CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patie...
(MedPage Today) -- Colchicine use was associated with fewer cardiovascular events and lower all-cause mortality
The prescription of the oral anticoagulant rivaroxaban to prevent thromboembolic episodes associated with orthopaedic surgery has dramatically increased since it was introduced. Rivaroxaban is beeing ...
Rivaroxaban is a factor-Xa-inhibitor which has been shown to be non-inferior to the vitamin-K-antagonist (VKA) warfarin in atrial fibrillation patients. In the manufacturer-sponsored trial, the rate o...
Rivaroxaban is increasingly used to treat patients with acute venous thromboembolism (VTE), a potentially life-threatening condition. Since absorption of rivaroxaban decreases from nearly 100% to 66% ...
Rivaroxaban is an anticoagulant prescribed for the management of atrial fibrillation. We describe a correlation between rivaroxaban and spontaneous vitreous hemorrhage.
Four-factor prothrombin complex concentrate (PCC) 50 iu/kg is able to swiftly restore haemostatic parameters in healthy subjects on rivaroxaban. We hypothesized that lower dosages of PCC may be suffic...